Jeannie Chin

Email

jeannie.chin@bcm.edu

Positions

Professor and Vivian L. Smith Endowed Chair in Neuroscience: Department of Neuroscience
Baylor College of Medicine

Associate Director: Graduate Program in Neuroscience
Baylor College of Medicine

Addresses

Baylor College of Medicine (Office): One Baylor Plaza, Room S707
Smith Medical Research Building
Houston, TX, 77030
United States

Education

Postdoctoral Training at Gladstone Institute of Neurological Disease and UCSF: San Francisco, California, United States; Alzheimer's disease

PhD from University of Texas Graduate School of Biomedical Sciences: Houston, Texas, United States; Neuroscience

BA from University of Texas, Austin: Austin, Texas, United States; Zoology

BS from University of Texas, Austin: Austin, Texas, United States; Biology

Professional Interests

Mechanisms of cognitive dysfunction in Alzheimer's disease, epilepsy, and other neurological disorders
Activity-dependent epigenetic regulation of gene expression
Neural stem cell dynamics
Corticothalamic network (dys)function in neurological disease
Read more at www.jeanniechinlab.com

Professional Statement

The focus of our research is to understand the cellular and network mechanisms underlying cognitive impairments in Alzheimer’s disease (AD) and other neurological disorders, and to identify therapeutic entry points for the treatment of these devastating diseases. We use a multi-disciplinary approach that combines biochemistry, molecular biology, in vivo physiology, and behavioral paradigms to link cellular alterations to memory deficits in mouse models of AD. We use video-recorded EEG to characterize patterns of (aberrant) brain activity in individual mice and correlate activity with performance in behavioral paradigms that test different aspects of memory and cognition. Finally, we use biochemical, molecular, and viral expression techniques to identify links between particular genes and cognitive dysfunction on a mouse-by-mouse basis. This integrated approach allows us to investigate the molecular basis of memory impairments in AD and identify therapeutic entry points for the treatment of this neurodegenerative disease.